Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Combined in Vitro and Ex Vivo Dose Finding Study - APIXART

Charité Campus Virchow-Klinikum0 个研究点目标入组 24 人开始时间: 2015年1月7日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Healthy Adult Subjects:
•no preexisting coagulation disorder, no preesisting diseases, agree to participate, no intake of anticoagulant drugs within 7 days before Study paritcipation;
•Patients after elective Hip- or Kneereplacement receive Apixaban (Eliquis®) for thromboprophylaxis, agree to participate, no preexisting coagulation disorders, normal kidney function, no intake of anticoagulant drugs except Apixaban, agree to participate

•Healthy Adult Subjects:
•Treatment as a Patient in Charite Hospital, pregnant or breastfeeding, refusal of participation, preexisting coagulation disorder, intake anticoagulant drug permanently or during the study, insufficient German language comprehension, a legal or governmental custodian, participate in a AMG trial;
•Patients: refusal of participation, pregnant or breastfeeding, preexisting coagulation disorder, intake anticoagulant drug permanently or during the study except Apixaban (Eliquis®), renal insuffiency, insufficient German language comprehension, a legal or governmental custodian, participate in a AMG trial

发起方

Charité Campus Virchow-Klinikum